Premium
Utility and prognostic value of 18 F‐FDG positron emission tomography‐computed tomography scans in patients with newly diagnosed multiple myeloma
Author(s) -
Aljama Mohammed A.,
Sidiqi M. Hasib,
Buadi Francis K.,
Lacy Martha Q.,
Gertz Morie A.,
Dispenzieri Angela,
Dingli David,
Muchtar Eli,
Fonder Amie L.,
Hayman Suzanne R.,
Hobbs Miriam A.,
Gonsalves Wilson I.,
Warsame Rahma M.,
Kourelis Taxiarchis,
Hwa Yi Lisa,
Kapoor Prashant,
Kyle Robert A.,
Leung Nelson,
Go Ronald S.,
Rajkumar S. Vincent,
Kumar Shaji K.
Publication year - 2018
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25279
Subject(s) - medicine , positron emission tomography , multiple myeloma , nuclear medicine , radiology , cohort , retrospective cohort study , standardized uptake value , positron emission tomography computed tomography
Positron emission tomography‐computed tomography (PET‐CT) can identify bony lesions, assess disease burden, and detect extramedullary disease (EMD) in patients with multiple myeloma. We retrospectively reviewed records of patients who underwent PET‐CT within 60 days of a new diagnosis (before therapy commenced) to identify the nature and prognostic impact of PET‐CT abnormalities. Patients ( N = 313) were seen from April 2005 through June 2017. Of the 234 patients (75%) with focal lesions (FLs), 182 (58%) had at least 3 FLs, 38 (12%) had EMD, and 204 (65%) had documented myelomatous lytic lesions. The median maximum standardized uptake value (SUV max ) for the entire cohort was 5.9 (range 1.5‐48.3). Presence of at least 3 FLs and EMD predicted inferior overall survival (OS); median OS was 57.8 months for patients with 3 or more FLs and 103.6 months for patients with fewer than 3 FLs ( P = .003). The median OS was 45.5 and 71.8 months for patients with and without EMD, respectively ( P = .004). No clear SUV max cutoff was predictive of progression‐free survival or OS. PET‐CT is a valuable tool for assessing disease burden and could provide prognostic information about a contemporary cohort of patients with newly diagnosed myeloma who received treatment with novel agents.